Display options
Cite
Braunstein MJ, Scott SS, Scott CM, et al. Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. J Oncol. 2011;2011:232037doi: 10.1155/2011/232037.
Braunstein, M. J., Scott, S. S., Scott, C. M., Behrman, S., Walter, P., Wipf, P., Coplan, J. D., Chrico, W., Joseph, D., Brodsky, J. L., & Batuman, O. (2011). Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. Journal of oncology, 2011232037. https://doi.org/10.1155/2011/232037
Braunstein, Marc J, et al. "Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101." Journal of oncology vol. 2011 (2011): 232037. doi: https://doi.org/10.1155/2011/232037
Braunstein MJ, Scott SS, Scott CM, Behrman S, Walter P, Wipf P, Coplan JD, Chrico W, Joseph D, Brodsky JL, Batuman O. Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. J Oncol. 2011;2011:232037. doi: 10.1155/2011/232037. Epub 2011 Sep 29. PMID: 21977030; PMCID: PMC3184436.
Copy Download .nbib Format: NLM
Share it on

J Oncol. 2011;2011:232037. doi: 10.1155/2011/232037. Epub 2011 Sep 29.

Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101.

Journal of oncology

Marc J Braunstein, Sadeaqua S Scott, Craig M Scott, Shannon Behrman, Peter Walter, Peter Wipf, Jeremy D Coplan, William Chrico, Danielle Joseph, Jeffrey L Brodsky, Olcay Batuman

Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA.

PMID: 21977030 PMCID: PMC3184436 DOI: 10.1155/2011/232037

Abstract

Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable, primarily due to the treatment-refractory/resistant nature of the disease. A rational approach to this compelling challenge is to develop new drugs that act synergistically with existing effective agents. This approach will reduce drug concentrations, avoid treatment resistance, and also improve treatment effectiveness by targeting new and nonredundant pathways in MM. Toward this goal, we examined the antimyeloma effects of MAL3-101, a member of a new class of non-ATP-site inhibitors of the heat shock protein (Hsp) 70 molecular chaperone. We discovered that MAL3-101 exhibited antimyeloma effects on MM cell lines in vitro and in vivo in a xenograft plasmacytoma model, as well as on primary tumor cells and bone marrow endothelial cells from myeloma patients. In combination with a proteasome inhibitor, MAL3-101 significantly potentiated the in vitro and in vivo antimyeloma effects. These data support a preclinical rationale for small molecule inhibition of Hsp70 function, either alone or in combination with other agents, as an effective therapeutic strategy for MM.

References

  1. Br J Haematol. 2011 Feb;152(4):367-79 - PubMed
  2. Nat Rev Cancer. 2007 Aug;7(8):585-98 - PubMed
  3. Curr Top Med Chem. 2006;6(11):1215-25 - PubMed
  4. EMBO J. 2006 Mar 8;25(5):1104-13 - PubMed
  5. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7871-6 - PubMed
  6. Blood. 2006 Apr 15;107(8):3098-105 - PubMed
  7. Mol Cell. 2010 Oct 22;40(2):238-52 - PubMed
  8. J Clin Oncol. 2005 Sep 10;23(26):6333-8 - PubMed
  9. Leuk Lymphoma. 2006 Mar;47(3):531-9 - PubMed
  10. Blood. 2010 Aug 5;116(5):679-86 - PubMed
  11. J Natl Cancer Inst. 2000 Oct 4;92(19):1564-72 - PubMed
  12. Blood. 2006 Nov 15;108(10):3441-9 - PubMed
  13. Clin Cancer Res. 2008 Mar 15;14(6):1649-57 - PubMed
  14. BMC Cancer. 2006 Jun 22;6:161 - PubMed
  15. Cancer Res. 2001 Apr 1;61(7):3071-6 - PubMed
  16. Cancer Res. 2002 Sep 1;62(17):4996-5000 - PubMed
  17. Curr Top Med Chem. 2009;9(15):1337-51 - PubMed
  18. ACS Chem Biol. 2010 Jun 18;5(6):611-22 - PubMed
  19. Blood. 2003 Nov 1;102(9):3340-8 - PubMed
  20. Br J Haematol. 2008 Aug;142(4):551-61 - PubMed
  21. Blood. 2006 Feb 1;107(3):1092-100 - PubMed
  22. Annu Rev Biochem. 2005;74:739-89 - PubMed
  23. Leukemia. 2010 Oct;24(10):1804-7 - PubMed
  24. Blood. 2009 Jan 22;113(4):846-55 - PubMed
  25. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 - PubMed
  26. Int J Hyperthermia. 2010;26(7):681-5 - PubMed
  27. Blood. 2004 Mar 1;103(5):1799-806 - PubMed
  28. Nat Rev Mol Cell Biol. 2008 Dec;9(12):944-57 - PubMed
  29. J Biol Chem. 2004 Dec 3;279(49):51131-40 - PubMed
  30. Nature. 2010 Jan 28;463(7280):549-53 - PubMed
  31. Expert Opin Biol Ther. 2002 Jan;2(1):3-24 - PubMed
  32. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9946-51 - PubMed
  33. Blood. 2007 Oct 1;110(7):2641-9 - PubMed
  34. Blood. 2006 Jun 15;107(12):4907-16 - PubMed
  35. Leukemia. 2009 Nov;23(11):1964-79 - PubMed
  36. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1764-8 - PubMed
  37. Transplant Proc. 2000 Nov;32(7):1745-6 - PubMed
  38. Cancer Res. 2007 Feb 15;67(4):1783-92 - PubMed
  39. J Clin Oncol. 2006 Feb 20;24(6):929-36 - PubMed
  40. Novartis Found Symp. 2008;291:115-31; discussion 131-40 - PubMed
  41. J Med Chem. 2010 Jun 24;53(12):4585-602 - PubMed
  42. Ann Rheum Dis. 2010 Jan;69(1):284-90 - PubMed
  43. Blood. 2006 Mar 15;107(6):2531-5 - PubMed
  44. Am J Hematol. 2011 Jan;86(1):57-65 - PubMed
  45. Cancer Res. 2006 Jan 1;66(1):184-91 - PubMed
  46. PLoS Biol. 2006 Nov;4(12):e423 - PubMed
  47. Biochemistry. 1994 Mar 8;33(9):2561-7 - PubMed
  48. Nat Chem Biol. 2007 Aug;3(8):498-507 - PubMed
  49. Blood. 2009 Mar 26;113(13):3040-9 - PubMed
  50. Genes Dev. 2005 Mar 1;19(5):570-82 - PubMed
  51. Cancer Cell. 2006 Apr;9(4):313-25 - PubMed
  52. Clin Cancer Res. 2002 Jul;8(7):2210-6 - PubMed
  53. Blood. 2005 Apr 15;105(8):3286-94 - PubMed
  54. Blood. 1986 Jun;67(6):1542-9 - PubMed

Publication Types

Grant support